Mineralys Therapeutics, Inc. Common Stock (MLYS)

Mineralys Therapeutics, Inc. Common Stock (MLYS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.9B; returns 1 day -4.3%, 1 week +1.2%, 1 year -49.6%.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for cardiorenal diseases driven by dysregulated aldosterone. The company's sole clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor.

Groups MLYS belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Cardiovascular Therapies
• Nephrology
• Metabolic Disorders
• Biopharmaceutical
• Clinical Stage
• Pharmaceuticals

MLYS financial model: income statement, cash flow and balance sheet